PT-141 (Bremelanotide)
MC4R-selective melanocortin agonist. Acts on CNS arousal pathways.
- Mechanism
- MC4R (and MC3R) agonist
- Half-life
- ~2 hours
- Onset
- 30–60 min post-injection
- Approval
- Approved (Vyleesi, HSDD)
- Sequence length
- 7 amino acids (cyclic)
Strengths
- · Approved therapeutic — real Phase 3 data
- · Acts on desire pathways centrally, not vascular tissue
- · Predictable onset window
Trade-offs
- · Nausea and transient blood-pressure elevation common
- · MC1R activity can cause hyperpigmentation with repeated use
